This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Here on Drug Channels , we have long highlighted the boom in provider-administered biosimilars. In contrast to the pharmacy market, adoption of these biosimilars is growing, prices are dropping, and formulary barriers continue to fall. As we demonstrate, health plans pay hospitals far above acquisition costs for biosimilars.
As many of you know, hospitals and health systems have emerged as significant participants in the specialty pharmacy industry. A new American Society of Hospital Pharmacists (ASHP) survey provides fresh insights into these specialty pharmacies. drug channels gets most of the attention.
Time for an update to the Drug Channels Institute (DCI) annual analysis of pharmacist salaries and employment. The retail pharmacy shakeout affected 2021 pharmacist employment. We found that retail pharmacies and drugstores employed fewer pharmacists, while hospitals and outpatient centers continued to add positions.
Despite what you may have heard, pharmacy participation in the 340B Drug Pricing Program continues to thrive. Drug Channels Institute’s latest analysis reveals that an astonishing 32,000 pharmacy locations —more than half of the entire U.S. d/b/a Drug Channels Institute. Read on for details and my commentary below.
Hospitals and health systems are rapidly expanding their internal specialty pharmacies—and they’re using questionable tactics to boost revenues and profits. Nearly two-thirds of the larger health system specialty pharmacies operate as the exclusive pharmacy within self-insured health systems’ networks.
In Drug Channels Institute’s list of the top 15 pharmacies of 2022 , we show that central-fill, mail pharmacies operated by large PBMs and health insurers have displaced retail chains as the largest prescription drug dispensers by revenues. d/b/a Drug Channels Institute. d/b/a Drug Channels Institute.
Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Click here to download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study Examines Consolidation and Vertical Integration of U.S.
In 2022, specialty pharmacies—via white, brown, and clear bagging—now constitute a meaningful share of the distribution channels for provider-administered oncology drugs. However, buy-and-bill appears to have rebounded substantially at hospitals. d/b/a Drug Channels Institute. Read on for full details and the latest data.
In the video excerpt below, I walk through a brief history of 340B contract pharmacies. I conclude with a “follow the dollar” example of 340B prescription economics with contract pharmacies. I conclude with a “follow the dollar” example of 340B prescription economics with contract pharmacies. All rights reserved.
Consider two apparently unrelated drug channel anomalies: In McKesson’s 2023 fiscal year, CVS bought $75 billion in pharmaceuticals from McKesson’s wholesale business—a jump of more than 35% compared with the previous year. Despite skyrocketing sales for anti-obesity GLP-1 drugs, many retail pharmacies are losing money on every prescription.
specialty pharmacies—via white, brown, and clear bagging—continue to displace buy-and-bill distribution channels for provider-administered oncology drugs. The battle for the specialty patient pits hospitals against insurers—and their respective specialty pharmacies. Hospitals, however, lose profits and face higher costs.
Drug Channels Institute’s (DCI’s) latest analysis finds that participants in the specialty pharmacy market continue to get more diverse—although revenues remain highly concentrated. Read on for DCI’s latest overview of the 2023 marketplace and revenues of the biggest market participants, along with key specialty pharmacy trends.
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. Despite skyrocketing sales for anti-obesity GLP-1 drugs, many retail pharmacies are losing money on every prescription. Click here to see the original post from December 2023.
National Association of Specialty Pharmacy (NASP) 2022 Annual Meeting & Expo. The National Association of Specialty Pharmacy (NASP) will host the NASP 2022 Annual Meeting & Expo September 19-22. Drug Channels, or any of its employees. d/b/a Drug Channels Institute. www.naspnet.org/annualmeeting.
Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCIs new live video webinar: Whats Next for Retail Pharmacy: Data, Debate, and Disruption This event will be broadcast live on: Friday, June 20, 2025 12:00 p.m. It is part of The Drug Channels 2025 Video Webinar Series.
Hospitals and health systems are building a major presence in the specialty pharmacy industry. As we demonstrate below, nine out of ten large hospitals now operate a specialty pharmacy. Hospitals and other healthcare providers account for one-third of all U.S. accredited specialty pharmacies.
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Outlook 2023. Today, I want to highlight three significant—and presumably unintended—drug channel consequences from the hastily-passed IRA legislation. d/b/a Drug Channels Institute.
Curl up with your favorite pumpkin-spiced blog and savor these stories harvested from the Drug Channels patch: Fresh insights about hospitals’ specialty drug profits SSR Update: Drug prices keep dropping My $0.02 d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.
The 340B contract pharmacy market shows little sign of slowing down. Drug Channels Institute’s exclusive analysis of the 2024 market reveals that: About 33,000 pharmacy locations—more than half of the entire U.S. For an updated look at what’s next for the 340B contract pharmacy market, join Adam J. Fein, Ph.D.,
Looks like pharmacy and PBM profiteering within the 340B Drug Pricing Program will never go out of style. Drug Channels Institute’s (DCI) latest analysis reveals that more than 33,000 pharmacy locations —more than half of the entire U.S. d/b/a Drug Channels Institute.
This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. For updated data on hospital-owned specialty pharmacies, see Chapter 3 of DCI's new 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers.
Two weeks ago, Paula and I had the pleasure of attending Asembia’s 2022 Specialty Pharmacy Summit at the wonderful Wynn Las Vegas. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Below, I violate Vegas code and tell you what happened there.
So grab your pillow case and stuff it with treats from the great Drug Channels pumpkin patch: Spooky! PBMs are conjuring a terrifying number of formulary exclusions for oncology drugs Eerie! Scream as Blue Cross Blue Shield frightfully overpays hospitals Shocking! d/b/a Drug Channels Institute. Brrr.did you hear that?
The stunning growth of specialty pharmacies in the 340B Drug Pricing Program has accelerated a troubling trend: Patients covered by commercial insurance and Medicare Part D are footing the bill for 340B savings. Our indisputable math exposes the little-understood economics behind specialty pharmacies in the 340B program.
The 340B contract pharmacy market shows little sign of slowing down. Drug Channels Institute’s exclusive analysis of the 2024 market reveals that: About 33,000 pharmacy locations—more than half of the entire U.S. For an updated look at what’s next for the 340B contract pharmacy market, join Adam J. Fein, Ph.D.,
It’s time for the annual update to Drug Channels Institute’s (DCI) analysis of pharmacist salaries and employment. Pharmacist employment at drug stores shrank but grew at supermarkets and mass merchants. What’s ahead for 340B-eligible hospitals? 2023 was another tough year for pharmacists working in retail settings. pharmacists.
Its time for Drug Channels annual look at pharmacist salaries and employment. There was more bad news, as employment in retail pharmacies and drugstores dropped by 8,500 positions in 2024, following a drop of 4,800 positions in 2023. Employment in mass merchants and supermarkets with pharmacies increased. Dr. Adam J.
Let’s turn up the heat with these sizzling news bites straight from the Drug Channels grill: SaveonSP gets sued Thoughts on the Medicaid accumulator rule opinion CVS buys AmerisourceBergen’s specialty pharmacy Fresh data on hospitals’ cancer drug profiteering Plus, Dr. Glaucomflecken explains Aetna’s prior authorization policies.
Asembia’s Specialty Pharmacy Summit 2022. Asembia's Specialty Pharmacy Summit 2022 is back! This is a must-attend event for anyone connected to specialty pharmacy. Plus, Doug Long from IQVIA and I will again lead the Featured Session, titled The Specialty Pharmacy Industry Update and Outlook. Gottlieb’s excellent book.
The 340B Drug Pricing Program has emerged as a growing source of profits for pharmacies and pharmacy benefit managers (PBMs). pharmacy industry—function as contract pharmacies for the hospitals and federal grantees that participate in the 340B program. It was meant to be part of patient care.” Fein, Ph.D.,
on the overall market, explained channel distortions from 340B contract pharmacies, and offered some policy recommendations. Click here to read the Drug Channels Institute letter to Senators Thune, Stabenow, Moore Capito, Baldwin, Moran, and Cardin. d/b/a Drug Channels Institute. I shared my $0.02 How could I not?
In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter. d/b/a Drug Channels Institute.
But who needs the Super Bowl when you can tackle this month’s selection of notable news stories, intercepted for you from the Drug Channels gridiron: Punt : Average list prices are unchanged for 2024 Trick Play : GSK tussles with PBMs over lower-priced products Rush! Check out the wonderful comments on this LinkedIn post. Great things ahead.
Please join me for my upcoming live video webinar, Drug Channels Outlook 2022 , on December 17, 2021, from 12:00 p.m. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Happy Thanksgiving, everyone! to 1:30 p.m. Will you be there, too?
Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2023. The webinar will be broadcast from the Drug Channels studio in beautiful downtown Philadelphia. d/b/a Drug Channels Institute. to 1:30 p.m.
Here’s a summer surprise for fans of the 340B Drug Pricing Program: Drug Channels has just obtained the 2021 figures from the Health Resources and Services Administration (HRSA)! Hospitals accounted for 87% of these skyrocketing 340B purchases. d/b/a Drug Channels Institute. The data tell a familiar story. billion (+$7.0
In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon Plus, the FDA preps you for Thursday with a regulatory soup review. d/b/a Drug Channels Institute.
During my recent Drug Channels Outlook 2025 video webinar, I tackled a wide range of crucial topicsincluding the controversial 340B Drug Pricing Program. As I explain in this video excerpt, we may finally see reform of this rapidly expanding program. All rights reserved. This Feed is for personal non-commercial use only.
I am pleased to announce that Drug Channels Institutes new 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers is now available for purchase and immediate download. drug pricing, reimbursement, and dispensing system. prescription drug channels. Pharmacies and Pharmacy Benefit Managers.
This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Drug Channels Outlook 2023. Here’s a summer surprise for fans of the 340B Drug Pricing Program: Drug Channels has just obtained the 2021 figures from the Health Resources and Services Administration (HRSA)! d/b/a Drug Channels Institute.
Drug Channels Institute’s latest review of contract pharmacies in the 340B Drug Pricing Program reveals that an astonishing 30,000 pharmacy locations—half of the entire U.S. pharmacy industry—now act as contract pharmacies for the hospitals and other healthcare providers that participate in the 340B program.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content